Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

84.43 -0.05

Overview

Share price change

24h

Current

Min

84.27

Max

84.53

Key metrics

By Trading Economics

Income

7M

-121M

Sales

14M

25M

EPS

-1.14

Profit margin

-481.149

Employees

594

EBITDA

-4.7M

-131M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+1.42% upside

Dividends

By Acuity

Next Earnings

5 Nov 2026

Market Stats

By TradingEconomics

Market Cap

63M

8.9B

Previous open

84.48

Previous close

84.43

News Sentiment

By Acuity

60%

40%

282 / 340 Healthcare

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Aug 2026, 23:56 UTC

News

Allegro Microsystems shares rose in after-market trading following Benchmark's initiation of coverage with a Buy rating. The stock closed at $42.52.

12 Aug 2026, 23:56 UTC

Social Media
News

STAAR Surgical shares are lower in after-market hours following an EPS miss, despite reporting second-quarter net sales of $93.5 million, a 111% increase.

12 Aug 2026, 23:51 UTC

News

Fossil Group Inc reported second-quarter sales of $209.7 million, exceeding expectations. Shares are trading sharply higher in after-market hours.

12 Aug 2026, 23:51 UTC

Social Media
News

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

12 Aug 2026, 23:51 UTC

Social Media
News

Harmonic Inc. reported strong Q2 results, with adjusted EPS of $0.24 and raised full-year guidance, leading shares higher in after-market hours.

12 Aug 2026, 23:51 UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

12 Aug 2026, 23:46 UTC

News

Cummins shares are higher in after-market trading following strong Q2 earnings of $9.46 billion, surpassing analyst expectations despite an adjusted EPS miss.

12 Aug 2026, 23:46 UTC

News

Wendy's shares declined in after-market hours after earlier gains on news of a potential buyout bid from Nelson Peltz's Trian Fund Management.

12 Aug 2026, 23:41 UTC

News

Granite Construction secures a $31 million contract for the Willow Rock Energy Storage Center, boosting its project portfolio. Shares are higher in after-market trading.

12 Aug 2026, 23:41 UTC

News

Mistras Group raised its fiscal year revenue guidance to $740-$755 million, driving shares higher in after-market trading. Adjusted EBITDA is expected around $93.5 million.

12 Aug 2026, 23:41 UTC

News
Social Media

Jack in the Box Inc. reports third-quarter earnings with EPS of $1.08, exceeding expectations. The stock is trading higher in after-market hours.

12 Aug 2026, 23:41 UTC

Social Media
News

EnerSys reported strong first-quarter results, with adjusted EPS of $3.66 and revenue of $935.6 million. Shares are higher in after-market trading.

12 Aug 2026, 23:41 UTC

News
Social Media

Coherent Corp shares fell in after-hours trading despite strong fourth-quarter results, including adjusted EPS of $1.74 and revenue of $2.05 billion.

12 Aug 2026, 23:41 UTC

Social Media
News

Enovix Corp shares are lower in after-market hours following mixed second-quarter results and lower-than-expected third-quarter revenue guidance.

12 Aug 2026, 23:36 UTC

Social Media
News

Cheniere Energy raised its 2026 earnings and production guidance despite a quarterly loss. Shares are higher in after-market trading amid rising natural gas prices.

12 Aug 2026, 23:36 UTC

News

Alexandria Real Estate Equities has priced a $1 billion offering of 7.250% junior subordinated notes, with shares modestly higher in after-market trading.

12 Aug 2026, 23:36 UTC

News

Nasdaq Inc. shares gained in after-market trading, reaching a monthly high as inflation data eased concerns over Federal Reserve rate hikes.

12 Aug 2026, 23:26 UTC

News

Red Robin Gourmet Burgers shares rose in after-market trading following a Q2 earnings report that showed adjusted earnings and revenue exceeding analyst expectations.

12 Aug 2026, 23:26 UTC

News

Trian Fund Management increased its stake in GE Healthcare Technologies to 3.1 million shares, contributing to a modest rise in after-market hours.

12 Aug 2026, 23:26 UTC

News
Correlated Moves

Vishay Intertechnology announced a quarterly dividend of $0.10 per share, enhancing investor sentiment as shares trade higher in after-market hours.

12 Aug 2026, 23:21 UTC

News

Duke Energy has restored power to over 171,000 customers in Greater Cincinnati. Shares are gaining in after-market hours amid this progress.

12 Aug 2026, 23:21 UTC

News

Allogene Therapeutics reports narrower net loss of $42.7 million, revenue of $4.64 million. Shares higher after positive trial results and $500 million securities offering announcement.

12 Aug 2026, 23:11 UTC

News

Goldman Sachs will acquire NEOS Investments for up to $2.25 billion, enhancing its asset management division with new income ETFs. Shares are higher in after-market trading.

12 Aug 2026, 23:06 UTC

News

Spero Therapeutics reports FDA approval of Utebzi and secures $105 million financing. Shares are trading higher in after-market hours.

12 Aug 2026, 23:06 UTC

News
Social Media

Meta Platforms faces a federal trial over youth safety violations. In after-market trading, shares are slightly higher despite ongoing legal challenges.

12 Aug 2026, 23:06 UTC

News

Phillips 66 shares rose in after-market trading following a strong second-quarter performance and a $10 billion increase in buyback authorization.

12 Aug 2026, 23:06 UTC

News

FormFactor Inc will participate in key investor conferences, boosting market interest. Shares are higher in after-market trading following the announcement.

12 Aug 2026, 23:06 UTC

Social Media
News

NextEra Energy has secured a $3.3 billion investment for natural gas projects in Texas and Pennsylvania, though shares are trading lower in after-market hours.

12 Aug 2026, 23:02 UTC

Social Media
News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

12 Aug 2026, 23:01 UTC

News

Kimball Electronics shares are lower in after-market trading following a quarterly adjusted EPS loss of $0.01, missing expectations of $0.39.

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

1.42% upside

12 Months Forecast

Average 85.56 USD  1.42%

High 95 USD

Low 80 USD

Based on 14 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

2

Buy

12

Hold

0

Sell

Sentiment

By Acuity

282 / 340 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat